To the full analysis
Kuros Biosciences stock: growth
KURN.SWKuros Biosciences reported $145.59M in revenue for fiscal 2025, up 60.5% on the prior year, up 97.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
30.9%
per year from 2006 to 2025, per share −6.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 97.5% | 34.3% | 30.9% |
| Revenue per share | 80.2% | 6.8% | −6.5% |
| Earnings | no data | −10.2% | no data |
| Earnings per share | no data | −28.6% | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $869K | −$41.47M | −$36.56M |
| 2007 | $43.07M | −$8.25M | −$6.39M |
| 2008 | $23.67M | −$31.22M | −$34.04M |
| 2009 | $10.93M | −$29.8M | −$18.35M |
| 2010 | $26.83M | −$1.75M | −$5.66M |
| 2011 | $1.89M | −$22.54M | −$10.79M |
| 2012 | $1.32M | −$11.06M | −$13.88M |
| 2013 | $1.2M | −$37M | −$23.12M |
| 2014 | $1.2M | −$40.84M | −$28.54M |
| 2015 | $7.63M | $7.47M | −$3.02M |
| 2016 | $1.27M | −$23.7M | −$10.73M |
| 2017 | $640.95K | −$19.79M | −$14.7M |
| 2018 | $858.2K | −$14.03M | −$16.2M |
| 2019 | $3.07M | −$13.51M | −$13.16M |
| 2020 | $4.85M | −$13.83M | −$11.35M |
| 2021 | $16.58M | −$9.05M | −$6.99M |
| 2022 | $21.59M | −$17.52M | −$9.3M |
| 2023 | $40.29M | −$16.48M | −$11.01M |
| 2024 | $90.69M | −$4.46M | $2.43M |
| 2025 | $145.59M | $2.54M | −$2.88M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.